Trial Profile
Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms PRIMARYS
- Sponsors Beaufour Ipsen Pharma; Ipsen
- 23 Mar 2021 Results of post-hoc analysis of two studies PRIMARYS5 (NCT00690898) and LEAD6 (NCT00701363) assessing most common oral medications used by patients with acromegaly during treatment with lanreotide autogel 120 mg , presented at the 103rd Annual Meeting of the Endocrine Society.
- 28 Mar 2014 New trial record